FierceBiotechFierceBioResearcherFierceBiotechITFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | traveler's diarrhea | C. jejune

Success in traveler's diarrhea jab trial


A new study published in Infection and Immunity says that an experimental vaccine against C. jejune, a major cause of traveler's diarrhea, worked to protect mice and monkeys in a clinical study and may well prove effective in humans as well.

"We are very excited about these results," says Dr. Patricia Guerry, the senior investigator. C. jejune also plays a role in other ailments, such as inflammatory bowel disease. Guerry has been working with grant money from the National Institute of Allergy and Infectious Diseases.

In particular, Guerry noted that monkeys were completely protected from diarrhea caused by C. jejune. Traveler's diarrhea is a common ailment for Americans journeying abroad, and it has inspired several development programs by biotech companies.

- read the story from Reuters

More stories about Vaccine   traveler's diarrhea   C. jejune  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.